Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC)

Juan I. Martínez-Salamanca, Estefania Linares, Javier González, Roberto Bertini, Joaquín A. Carballido, Thomas Chromecki, Gaetano Ciancio, Sia Daneshmand, Christopher P. Evans, Paolo Gontero, Axel Haferkamp, Markus Hohenfellner, William C. Huang, Theresa M. Koppie, Viraj A. Master, Rayan Matloob, James M. McKiernan, Carrie M. Mlynarczyk, Francesco Montorsi, Hao G. NguyenGiacomo Novara, Sascha Pahernik, Juan Palou, Raj S. Pruthi, Krishna Ramaswamy, Oscar Rodriguez Faba, Paul Russo, Shahrokh F. Shariat, Martin Spahn, Carlo Terrone, Derya Tilki, Daniel Vergho, Eric M. Wallen, Evanguelos Xylinas, Richard Zigeuner, John A. Libertino

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Renal cell carcinoma (RCC) extension into the renal vein or the inferior vena cava occurs in 4 %-10 % of all kidney cancer cases. This entity shows a wide range of different clinical and surgical scenarios, making natural history and oncological outcomes variable and poorly characterized. Infrequency and variability make it necessary to share the experience from different institutions to properly analyze surgical outcomes in this setting. The International Renal Cell Carcinoma-Venous Tumor Thrombus Consortium was created to answer the questions generated by competing results from different retrospective studies in RCC with venous extension on current controversial topics. The aim of this article is to summarize the experience gained from the analysis of the world's largest cohort of patients in this unique setting to date.

Original languageEnglish (US)
Article number404
JournalCurrent urology reports
Volume15
Issue number5
DOIs
StatePublished - May 2014

Keywords

  • Cohort
  • Consortium
  • Inferior vena cava
  • Multi-institutional
  • Radical nephrectomy
  • Renal cell carcinoma
  • Thrombectomy
  • Tumor thrombus

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC)'. Together they form a unique fingerprint.

Cite this